IN THE SPOTLIGHT

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

FDA Approval of Sevabertinib Expands Treatment Options for HER2-Mutated NSCLC

FDA Approval of Sevabertinib Expands Treatment Options for HER2-Mutated NSCLC

Dr Le on the Clinical Significance of the FDA Approval of Sevabertinib for Locally Advanced/Metastatic HER2+ NSCLC

Dr Le on the Clinical Significance of the FDA Approval of Sevabertinib for Locally Advanced/Metastatic HER2+ NSCLC

Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

Natural polysaccharide riclin acts as an immune adjuvant to enhance chemotherapy efficacy in NSCLC

Natural polysaccharide riclin acts as an immune adjuvant to enhance chemotherapy efficacy in NSCLC